Építés alatt – nem éles oldal
Belépés
Résztvevőt keres3. fázis

A Phase III Study of CLS2901C in Patients With Osteoarthritis of the Knee

A legfontosabb adatok

Ki végzi
CellSeed Inc.
Hol
Japán6 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Toboroz
Fázis
3. fázis
Résztvevők
96 fő, tervezett
Kezdés
2023. okt. 20.
Várható befejezés
2031. júl. 31.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport nem kap vizsgálati kezelést, összehasonlításként.
A vizsgált kezelések
  • CLS2901C (human [allogeneic] chondrocyte sheets)
A regiszteradat frissítve
2026. július 9.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for adults with knee osteoarthritis and cartilage damage who can have a knee bone-realignment surgery (proximal tibial osteotomy). It compares the surgery alone with the surgery plus CLS2901C cartilage cell sheets.

Életkor
20 to 79 years
Nem
Male and female
A betegség stádiuma
Knee osteoarthritis Kellgren-Lawrence Grade 2 to 4 on X-ray. Knee bends to at least 120 degrees and straightens to within 5 degrees. Each cartilage defect is at least 4 cm2, with a total of 21 cm2 or less if there are several. BMI under 30.
Korábbi kezelés
In the target knee: no ligament reconstruction, meniscal suturing, total meniscectomy, bone marrow stimulation, regenerative medicine products, cell products (including PRP) or gene therapy. No hyaluronic acid or opioid for severe knee pain in the last 1 month. No corticosteroid or immunosuppressive drug in the knee in the last 3 months. No PRP in the last 6 months. No nerve radiofrequency ablation in the knee in the last 1 year. No osteotomy in the other knee. No mesenchymal stem cell treatment ever. Smokers must stop from 3 months before surgery until the bone heals.

A részvétel fő kizáró okai

  • Ligament or meniscus injury in the target knee that needs surgical repair, or surgery needed on the other knee
  • Rheumatoid arthritis or other whole-body inflammatory disease, or active infection
  • Cancer now, suspected, or in the past 5 years
  • Poorly controlled diabetes (HbA1c >7.0% (53 mmol/mol)) or other serious liver, kidney, heart, lung or blood disease
  • Pregnant or breastfeeding women, or women who can become pregnant and do not use the required birth control

A regiszter feltételei, szó szerint

Mind a 26 feltétel megnézéseKevesebb

Ki vehet részt

  • Male or female aged 20 to 79 years at informed consent
  • Diagnosis of OAK classified as Kellgren-Lawrence (K-L) Grade 2 to 4 based on plain lower extremity X-ray
  • OAK eligible for proximal tibial osteotomy based on the following criteria: Range of motion (ROM): >=120 degree flexion, <=5 degree extension
  • Preoperative cartilage defect of the femoral condyle/trochlear groove or medial tibial condyle with an area of >=4 cm2 per defect site
  • Total defect area of <=21 cm2 in individuals with multiple cartilage defects
  • Body mass index (BMI) <30
  • No coexisting ligament injury requiring surgery, and no meniscal injury requiring suturing or surgical repair other than partial resection, in the target knee
  • No history of ligament reconstruction, meniscal suturing, total meniscectomy or bone marrow stimulation, and no history of treatment with regenerative medicine products (including investigational products), cell processing products(including PRP) or gene therapy, in the target knee
  • No history of treatment with hyaluronic acid products and/or opioid for severe pain in the target knee within 1 month prior to informed consent
  • No history of treatment with corticosteroid products and/or immunosuppressive drug in the target knee within 3 months prior to informed consent
  • No history of platelet-rich plasma (PRP) therapy within 6 months prior to informed consent
  • Non-smoker; provided, however, that smokers will be eligible for study entry if they consent to abstain from smoking from 3 months prior to proximal tibial osteotomy or proximal tibial osteotomy+RMSC until postoperative bone healing
  • Written informed consent to participate in the study on a voluntary basis
  • No history of treatment with radiofrequency ablation of peripheral nerves in the knee joint within 1 year prior to informed consent
  • No history of proximal tibial osteotomy in the non-target knee
  • No history of treatment using mesenchymal stem cells, mesenchymal stromal cells, or stem cell culture supernatant

Ki nem vehet részt

  • Requires surgical treatment of the non-target knee during the study period
  • Received treatment as part of another clinical study within the past 6 months, currently participating in another clinical study, or planning to participate in another clinical study while also participating in the present study
  • Any coexisting illness that would interfere with surgery under general anesthesia or that would affect knee surgery
  • Systemic inflammatory disease such as rheumatoid arthritis
  • Systemic Active infectious disease such as bacterial, fungal or viral infection
  • Serious disease such as liver disorder, renal disorder, heart disease, lung disease, blood disease or metabolic disease that would make the patient unsuitable for study entry in the opinion of the investigator
  • Diagnosed or suspected malignant tumor or history of malignant tumor within the past 5 years
  • Known history of hypersensitivity to bovine-derived materials. 15) Any other reason the investigator deems the subject unsuitable for study entry
  • Uncontrolled psychiatric disorder. 9) Poorly-controlled diabetes (HbA1c: >7.0%). 10) septic arthritis of the target knee. 11) Women who are pregnant or breastfeeding, or women of childbearing potential. Women of childbearing potential must agree to use the following contraceptive methods (i.e., contraceptives and medical devices that are approved/certified in Japan) or to abstain completely from sexual intercourse from the time of informed consent and for the study duration (excluding the follow-up period) in order to be eligible for study entry. (a) Primary contraceptive methods: Oral contraceptives, intrauterine devices (IUDs) including progesterone-releasing systems. (b) Adjunctive contraceptive methods: Condoms Use of a primary contraceptive method is mandatory, whereas use of the adjunctive contraceptive method must be in conjunction with a primary contraceptive method. Given that oral contraceptive doses can be missed and that their effects may be diminished when used concomitantly with other medications or dietary health supplements, subjects should consider changing their primary contraceptive method
  • Known history of hypersensitivity to antibiotics (benzylpenicillin potassium, streptomycin sulfate, amphotericin B)

A fő feltételek kérdésként

Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.

  • 20 és 79 év között vagy?

Ez a vizsgálat jelenleg itt érhető el: Japán.

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

To evaluate the efficacy and safety of CLS2901C human allogenic chondrocyte sheets used in the osteotomy + RMSC group compared to in the osteotomy alone group of patients with osteoarthritis of the knee (OAK).

A vizsgálat 2 csoportja

  • the osteotomy monotherapy groupNincs vizsgálati kezelés, összehasonlításként

    the osteotomy monotherapy

  • the osteotomy + RMSC combination therapy groupA vizsgált kezelés

    the osteotomy + RMSC combination therapy \*RMSC combination therapy R: Resection of unhealthy tissue MS: Marrow arrow Stimulating=MSCs Recruitment C: Covered by Chondrocyte sheets

    Kezelés: CLS2901C (human [allogeneic] chondrocyte sheets)

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Phase III Study Evaluating the Efficacy and Safety of CLS2901C in Patients With Osteoarthritis of the Knee
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
Kérdések a feltételekről
Forrás: NCT06549686: ki vehet részt
A regiszteradat frissítve
2026. július 9.